Charles River Laboratories · Health Care
CRL
$224.35
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States.CharlesRiverLaboratoriesInternational,Inc.是一家美国制药和生物技术合同研究组织（CRO），总部位于美国马萨诸塞州威尔明顿。
Speculative / unprofitable投机／未盈利
Large cap大盘
$11B
Engine stance引擎立场2026-07-20
Neutral — no clear edge中性 — 无明显优势
The bottoming setup is not yet confirmed (price still below the 10-day average) and oscillators are already extended/ove筑底形态尚未确认（价格仍位于 10 日均线下方），且摆动指标已过热——此处入场风险较高。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Key Statistics关键统计
Price价格
$224.35
4.0% below 52-week high低于52周高点 4.0%
Market Cap市值
$11B
Normal volume正常成交量
Beta贝塔
1.35
Moves about 1.4x the market波动幅度约为市场的 1.4 倍
RSI (14)RSI（14）
61
Elevated偏高
Next Earnings下次财报
2026-08-05 (17d)
Volatility Rank波动率分位
43th pctile
hist. vol. percentile历史波动率分位数
Short Interest空头兴趣
8.8% of float
Performance价格表现
| Period周期 | CRL | S&P 500 | vs Index对比指数 |
|---|---|---|---|
| 1 Week近1周 | -3.9% | -1.5% | Lagged the index by 2.4 points落后指数 2.4 个百分点 |
| 1 Month近1月 | +23.0% | +0.6% | Beat the index by 22.4 points跑赢指数 22.4 个百分点 |
| 3 Months近3月 | +22.0% | +4.7% | Beat the index by 17.3 points跑赢指数 17.3 个百分点 |
| 6 Months近6月 | +2.1% | +7.8% | Lagged the index by 5.7 points落后指数 5.7 个百分点 |
| Year to date年初至今 | +10.8% | +9.1% | Beat the index by 1.7 points跑赢指数 1.7 个百分点 |
| 1 Year近1年 | +43.2% | +19.4% | Beat the index by 23.8 points跑赢指数 23.8 个百分点 |
Technicals技术面
RSI (14)RSI（14）
61
Elevated偏高
vs 50-day相对50日均线
+16.9% vs 50-day avg
vs 200-day相对200日均线
+21.7% vs 200-day avg
Volatility rank波动率分位
43th percentile 分位
Engine reference levels — not advice引擎参考水平 — 非投资建议
Buy zone买入区间
$219.50
Don't chase above不追高于
$224.40
Stop止损
$181.60
Extended — wait for a pullback过度拉伸 — 等待回撤
Earnings财务业绩
17
days until next report天后公布财报
2026-08-05
Estimates being cut预期下调
Earnings call transcripts — coming soon财报电话会议记录 — 即将上线
Valuation估值
| Multiple指标 | CRL | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/B市净率 | 3.49x | 3.52 | 50% |
| P/S市销率 | 2.75x | 3.02 | 53% |
| Earnings yield盈利收益率 | -1.31% | 2.72 | 20% |
| FCF yield自由现金流收益率 | 4.70% | 3.94 | 58% |
| Shareholder yield股东收益率 | 3.27% | 1.89 | 68% |
| EV/EBITDA企业价值/EBITDA | 25.27x | 18.21 | 30% |
| P/FCF市值/自由现金流 | 21.30x | 22.42 | 52% |
Analyst price targets — coming soon分析师目标价 — 即将上线
Financials财务数据
Revenue营业收入
5yr CAGR5年复合增速: 6.5%
Earnings Per Share每股收益
Free Cash Flow自由现金流
Margins利润率
-4.6%Return on Equity股本回报率
-2.0%Return on Assets资产回报率
Leverage杠杆
| Net debt / EBITDA净债务/EBITDA | -0.50 |
| Current ratio流动比率 | 1.29 |
Capital Allocation资本配置
| Buybacks (TTM)回购（TTM） | $360.7M |
| Stock-based comp股权薪酬 | $71.1M |
| Share count change (1y)股数变化（1年） | -3.8% |
Piotroski皮奥特罗斯基 4/7
Altman Z阿尔特曼Z: grey (2.6)
Clean稳健
Snapshot Gauges综合指标
Valuation vs Sector估值相对行业
Roughly fair vs sector相对行业估值合理
Cheaper than 48% of its sector on blended multiples综合估值倍数低于行业内 48% 的公司
Beta市场敏感度
1.35×
0.21×3×
Moves about 1.4× the market波动幅度约为市场的 1.4 倍
Financial Health财务健康
4/7
Altman阿尔特曼: grey
Weak financial health财务健康状况偏弱
Dividend分红
—
Does not pay a dividend不派发股息
Why Is It Moving为何波动
Sector / Theme行业/主题
Health Care (Equal-Weight) theme — #6 of 46 themes「医疗保健（等权）」主题 — 46 个主题中第 6 位
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Short interest changed +20.5%空头仓位变动 +20.5%
Technical技术面
CRL took relative-strength leadershipCRL 取得相对强弱领先
Options Positioning期权持仓
Market makers are net long gamma — price pinned near current level做市商净持有正伽玛，价格倾向于在当前水平附近震荡
Expected daily move预期日波动
±3.67%
Expected weekly move预期周波动
±8.21%
Call wall看涨密集区
$230
25d risk reversal25d风险逆转
-2.1%
Skew: 偏斜：balanced
Ownership & Smart Money持仓与聪明钱
Insider activity内部人员活动: -$0.1M net (0 buyers, 1 sellers)-$0.1M 净值（0 买家，1 卖家）
| Fund基金 | Grade评级 | Activity动作 | % of portfolio组合占比 | As of截至 |
|---|---|---|---|---|
| Soros Fund Management | B | exitexit | 0.0% | 2026-03-31 |
Signal History信号历史
TURN SIGNALED
BOTTOMING
Jul 16, 2026
CRL took relative-strength leadershipCRL 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $229.16.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$229.16。
Jul 15, 2026
CRL daily MACD crossed downCRL 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $228.22.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$228.22。
Jul 9, 2026
CRL made a new 52-week highCRL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $233.60.价格创出52周新高 — 全市场关注的动量/趋势极值。$233.60。
Jul 9, 2026
CRL RSI reached overboughtCRL RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $233.60.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$233.60。
Jul 6, 2026
Golden cross on CRLCRL 金叉
The 50-day average crossed above the 200-day — a slow, widely-watched bullish trend signal. $231.43.50日均线上穿200日均线 — 一个滞后但广受关注的看多趋势信号。$231.43。
Jun 30, 2026
CRL made a new 52-week highCRL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $226.79.价格创出52周新高 — 全市场关注的动量/趋势极值。$226.79。
Jun 25, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jun 25, 2026
CRL RSI reached overboughtCRL RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $212.71.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$212.71。
Jun 24, 2026
CRL took relative-strength leadershipCRL 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $202.10.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$202.10。
Jun 24, 2026
CRL daily MACD crossed upCRL 日线MACD上穿
The daily MACD histogram turned positive — fast and noisy, context rather than a standalone trigger. $202.10.日线MACD柱状图转正 — 快速且嘈杂，仅作背景。$202.10。
Showing last 15 of显示最近15条，共 105 signals条信号
Factor Profile因子特征
Composite factor score综合因子得分: 0.08
Value价值
-0.7
Quality质量
+0.9
Investment资本投入
+0.8
Shareholder payout股东回报
-0.2
Low volatility低波动
-0.5
Low market beta低市场敏感度
-0.7
Earnings quality盈利质量
+1.2
Short interest空头兴趣
-0.4
Company Profile公司档案
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States.CharlesRiverLaboratoriesInternational,Inc.是一家美国制药和生物技术合同研究组织（CRO），总部位于美国马萨诸塞州威尔明顿。
Get the full picture获取完整视图
Nightly signals, options flow, and factor analysis across all S&P 500 names.每日更新的信号、期权资金流向和因子分析，覆盖所有标普500成分股。